We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




The Benefits of Comprehensive Renin Testing Capabilities

By Dr. Matthias Herkert, DRG International
Posted on 11 Aug 2010
Print article
In the United States, one third of the American adults have high blood pressure or hypertension, and among those, almost one third even do not know that they had the condition. Even worse, among those who received treatment, only one third had their blood pressure under control. However, hypertension increases the chance for developing heart disease, stroke and other serious health conditions.
In today's hard economic environment, time – and money – are of the essence. In the world of medical testing, doctors, nurses, and practitioners struggle to find the most significant and still cost-effective tools to offer patients quality care and early warning.
The enzyme Renin is a key factor in the regulation of arterial blood pressure. Renin belongs to the Renin-Angiotensin-Aldosterone System (RAAS) that controls blood pressure, renal blood flux, glomerular filtration, and the body's balance of electrolytes and fluids. Plasma active Renin is a good index for the activity of the RAAS. In case of dysfunction of the RAAS, the Renin assay will allow clinical implications for diagnosis, treatment, and follow up.
The juxtaglomerular cells of the kidneys produce Renin as a reaction to low intra-renal blood pressure, reduced sodium reabsorption, hypokalemia or activity of the sympathetic nervous system. When active Renin enters the bloodstream, it mediates cleavage of angiotensinogen into the precursor peptide angiotensin I, and ultimately leads to the production of angiotensin II, which causes a rise in blood pressure, while the increase of aldosterone helps the body to retain sodium. Once blood pressure has been stabilized, the additional Renin and aldosterone which were created are metabolized, and the body ceases their productions.

In some patients, the kidneys continue to produce Renin after blood pressure has been stabilized. This causes the patient's blood pressure to rise. While dietary changes can alleviate the problem, it is sometimes necessary to take other measures. In these cases, doctors may request Renin tests in order to get a better estimate of Renin levels in the body and to see if Renin overproduction is the cause of a patient's blood pressure problems.

Normal Renin values range from 1.9 to 40 pg/mL. A high Renin value can be a harbinger for kidney disease, a blocked artery located close to a kidney, Addison's disease, cirrhosis, a hemorrhage, or malignant high blood pressure. Conversely, low Renin values may indicate the presence of Conn's syndrome. Either condition is potentially life threatening. According to the Centers for Disease Control and Prevention, there were 23,965 hypertension-related deaths in 2007.

Active Renin is an important marker for hypertensive patients and for the therapeutic follow up of high blood pressure. With a third of the US population affected by the disease, it is important to be able to get a high volume of tests accomplished with efficiency. This advancement is an important achievement for laboratory efficiency and expediency for patient results.

Existing methods to estimate Renin in blood either determined Renin activity or specifically measured the concentration of the active Renin. Both approaches had drawbacks as they either needed additional sample extraction, used radioactive quantification or were available only as closed systems.

Dr. Matthias Herkert is the Senior Scientist in the research and development department of DRG Instruments GmbH, a wholly owned subsidiary of DRG International. DRG International's active Renin ELISA is the first non-radioactive open system, that allows for quantification of active Renin testing without extraction.
At DRG, Dr. Herkert is responsible for development of new ELISA kits. He also oversees collaboration with project partners, including university hospitals and research groups. In addition, Dr. Herkert represents DRG in National and International Congresses. With approximately 20 years of experience at leading institutions, Dr. Herkert has a strong theoretical and practical knowledge in the fields of biochemistry and neuroscience, as well as ELISA assay development.
Founded in 1970 by Dr. Cyril E. Geacintov, DRG International, Inc. is a leading specialty medical equipment and diagnostics manufacturer with operations in more than 100 countries.

Related Links:
New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.